European Journal of Cancer
Volume 46, Issue 5 , Pages 869-879 , March 2010

Predictive biomarkers for personalised anti-cancer drug use: Discovery to clinical implementation

  • Nayef A. Alymani

      Affiliations

    • Section of Translational Medical Sciences, Division of Applied Medicine, School of Medicine and Dentistry, Institute of Medical Sciences, University of Aberdeen, Foresterhill, Aberdeen AB25 2ZD, Scotland, United Kingdom
    • Health Economics Research Unit, Division of Applied Health Sciences, School of Medicine and Dentistry, University of Aberdeen, Foresterhill, Aberdeen AB25 2ZD, Scotland, United Kingdom
    • ,
  • Murray D. Smith

      Affiliations

    • Health Economics Research Unit, Division of Applied Health Sciences, School of Medicine and Dentistry, University of Aberdeen, Foresterhill, Aberdeen AB25 2ZD, Scotland, United Kingdom
    • ,
  • David J. Williams

      Affiliations

    • Department of Clinical Pharmacology, NHS Grampian Aberdeen Royal Infirmary, Foresterhill, Aberdeen AB25 2ZN, Scotland, United Kingdom
    • ,
  • Russell D. Petty

      Affiliations

    • Section of Translational Medical Sciences, Division of Applied Medicine, School of Medicine and Dentistry, Institute of Medical Sciences, University of Aberdeen, Foresterhill, Aberdeen AB25 2ZD, Scotland, United Kingdom
    • Department of Medical Oncology, NHS Grampian Aberdeen Royal Infirmary, Foresterhill, Aberdeen AB25 2ZN, Scotland, United Kingdom
    • Corresponding Author InformationCorresponding author: Address: Section of Translational Medical Sciences, Division of Applied Medicine, School of Medicine and Dentistry, Institute of Medical Sciences, University of Aberdeen, Foresterhill, Aberdeen AB25 2ZD, Scotland, United Kingdom. Tel.: +44 (0) 1224555914; fax: +44 (0) 1224555766.

Received 15 September 2009 ,Revised 18 December 2009 ,Accepted 6 January 2010.

References 

  1. Collins I, Workman P. New approaches to molecular cancer therapeutics. Nat Chem Biol. 2006;2(12):689–700
  2. NIH, Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Toxicol 2001;69(3):2020–27.
  3. Kelloff GJ, Sigman CC. New science-based endpoints to accelerate oncology drug development. Eur J Cancer. 2005;41(4):491–501
  4. Sarker D, Workman P. Pharmacodynamic biomarkers for molecular cancer therapeutics. Adv Cancer Res. 2006;96:213–268[ate of Pubaton]
  5. Ludwig JA, Weinstein JN. Biomarkers in cancer staging, prognosis and treatment selection. Nat Rev Cancer. 2005;5(11):845–856
  6. Maruvada P, Srivastava S. Joint National Cancer Institute-Food and Drug Administration workshop on research strategies, study designs, and statistical approaches to biomarker validation for cancer diagnosis and detection. Cancer Epidemiol Biomarkers Prev. 2006;15(6):1078–1082
  7. Sawyers CL. The cancer biomarker problem. Nature. 2008;452(7187):548–552
  8. Chau CH, Rixe O, McLeod H, et al. Validation of analytic methods for biomarkers used in drug development. Clin Cancer Res. 2008;14(19):5967–5976
  9. Lee JW, Devanarayan V, Barrett YC, et al. Fit-for-purpose method development and validation for successful biomarker measurement. Pharm Res. 2006;23(2):312–328
  10. Cummings J, Ward TH, Greystoke A, et al. Biomarker method validation in anticancer drug development. Br J Pharmacol. 2008;153(4):646–656
  11. Chin L, Gray JW. Translating insights from the cancer genome into clinical practice. Nature. 2008;452(7187):553–563
  12. Petty RD, Nicolson MC, Kerr KM, et al. Gene expression profiling in non-small cell lung cancer: from molecular mechanisms to clinical application. Clin Cancer Res. 2004;10(10):3237–3248
  13. Petty RD, Kerr KM, Murray GI, et al. Tumor transcriptome reveals the predictive and prognostic impact of lysosomal protease inhibitors in non-small-cell lung cancer. J Clin Oncol. 2006;24(11):1729–1744
  14. van’t Veer LJ, Bernards R. Enabling personalized cancer medicine through analysis of gene-expression patterns. Nature. 2008;452(7187):564–570
  15. Debucquoy A, Haustermans K, Daemen A, et al. Molecular response to cetuximab and efficacy of preoperative cetuximab-based chemoradiation in rectal cancer. J Clin Oncol 2009;(March) [ePublished Ahead of Print].
  16. Martinkova J, Gadher SJ, Hajduch M, et al. Challenges in cancer research and multifaceted approaches for cancer biomarker quest. FEBS Lett. 2009;583(11):1772–1784
  17. Shah VP. The history of bioanalytical method validation and regulation: evolution of a guidance document on bioanalytical methods validation. AAPS Journal. 2007;9(1):[Arte Number: 5. ate of Pubaton]
  18. Fontaine N, Rosengren B. Directive 2001/20/EC of the european parliament and of the council: on the approximation of the laws, regulations and administrative provisions of the members states relating to the implementation of good clinical practice in the conduct of clinical trails on medicinal products for human use. OJEC 4-4-2001.
  19. FDA. Guidance for industry: bioanalytical method validation. 2001.
  20. Stiles T, Grant V, Mawbey N. Good clinical laboratory practice (GCLP): a quality system for laboratories that undertake the analysis of samples from clinical trials. Suffolk, UK: British Association of Research Quality Assurance (BARQA); 2003;
  21. Lee JW, Weiner RS, Sailstad JM, et al. Method validation and measurement of biomarkers in nonclinical and clinical samples in drug development: a conference report. Pharm Res. 2005;22(4):499–511
  22. Korfmacher WA. Principles and applications of LC–MS in new drug discovery. Drug Discov Today. 2005;10(20):1357–1367
  23. Smolec J, DeSilva B, Smith W, et al. Bioanalytical method validation for macromolecules in support of pharmacokinetic studies. Pharm Res. 2005;22(9):1425–1431
  24. Shah VP, Midha KK, Findlay JWA, et al. Bioanalytical method validation – a revisit with a decade of progress. Pharm Res. 2000;17(12):1551–1557
  25. Nowatzke W, Wood E. Best practices during bioanalytical method validation for the characterisation of assay reagents and the evaluation of analyte stability in assay standards quality controls and study samples. AAPS J. 2007;9:E117–E122
  26. Amur S, Frueh F, Lesko LJ, et al. Integration and use of biomarkers in drug development, regulations and clinical practice: a US regulatory perspective. Biomarkers Med. 2008;2(3):305–311
  27. Sargent DJ, Conley BA, Allegra C, et al. Clinical trial designs for predictive marker validation in cancer treatment trials. J Clin Oncol. 2005;23(9):2020–2027
  28. Brunner N, Vang Nielsen K, Offenberg H, et al. Biomarkers for therapeutic efficacy. Eur J Cancer. 2007;5(5 Suppl.):129–142
  29. Goodsaid F, Frueh F. Biomarker qualification pilot process at the US Food and Drug Administration. AAPS J. 2007;9(1):E105–E108
  30. Goodsaid F, Frueh F. Process map proposal for the validation of genomic biomarkers. Pharmacogenomics. 2006;7(5):773–782
  31. Burckart GJ, Amur S, Goodsaid FM, et al. Qualification of biomarkers for drug development in organ transplantation. Am J Transplant. 2008;8(2):267–270
  32. Tsao MS, Sakurada A, Cutz JC, et al. Erlotinib in lung cancer – molecular and clinical predictors of outcome. N Engl J Med. 2005;353(2):133–144
  33. Waring PM. Matching patients with drugs: triumphs and challenges. Personalized Med. 2006;3(3):335–344
  34. Moretti F, Belardelli F. Needs and challenges in translational medicine: filling the gap between basic research and clinical applications. ISTISAN Congr. 2008;08(C7):
  35. Seymour MT, Maughan TS, Ledermann JA, et al. Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial. Lancet. 2007;370(9582):143–152
  36. Braun MS, Richman SD, Quirke P, et al. Predictive biomarkers of chemotherapy efficacy in colorectal cancer: results from the UK MRC FOCUS trial. J Clin Oncol. 2008;26(16):2690–2698
  37. McShane LM, Altman DG, Sauerbrei W, et al. REporting recommendations for tumour MARKer prognostic studies (REMARK). Eur J Cancer. 2005;41(12):1690–1696
  38. Hayes DF, Bast RC, Desch CE, et al. Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers. J Natl Cancer Inst. 1996;88(20):1456–1466[see comment]
  39. Williams SA, Slavin DE, Wagner JA, et al. A cost-effectiveness approach to the qualification and acceptance of biomarkers. Nat Rev Drug Discovery. 2006;5(11):897–902
  40. Wagner JA, Williams SA, Webster CJ. Biomarkers and surrogate end points for fit-for-purpose development and regulatory evaluation of new drugs. Clin Pharmacol Ther. 2007;81(1):104–107
  41. Chatterjee SK, Zetter BR. Cancer biomarkers: knowing the present and predicting the future. Future Oncol. 2005;1(1):37–50
  42. Gown AM. Current issues in ER and HER2 testing by IHC in breast cancer. Mod Pathol. 2008;21:S8–S15
  43. Van Cutsem E, Kang Y, Chung H, et al. Efficacy results from the ToGA trial: a phase III study of trastuzumab added to standard chemotherapy (CT) in first-line human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (GC). J Clin Oncol. 2009;27(18S):LBA4509;[Meeting Abstracts]
  44. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004;304(5676):1497–1500
  45. Mok TS, Wu Y, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361(10):947–957
  46. Karapetis CS, Khambata-Ford S, Jonker DJ, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med. 2008;359(17):1757–1765
  47. De Roock W, Piessevaux H, De Schutter J, et al. KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann Oncol. 2008;19(3):508–515
  48. Di Fiore F, Blanchard F, Charbonnier F, et al. Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by cetuximab plus chemotherapy. Br J Cancer. 2007;96(8):1166–1169
  49. Lievre A, Bachet JB, Le Corre D, et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res. 2006;66(8):3992–3995
  50. Linardou H, Dahabreh IJ, Kanaloupiti D, et al. Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. Lancet Oncol. 2008;9(10):962–972

PII: S0959-8049(10)00002-X

doi: 10.1016/j.ejca.2010.01.001

European Journal of Cancer
Volume 46, Issue 5 , Pages 869-879 , March 2010

Article Tools

* Image Usage & Resolution